Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2019-10-16
2019-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reproducibility of Acute Caffeine Effect
NCT06606639
Caffeine, Resistance Exercise and EMG
NCT06606652
Caffeine, Resistance Exercise and Muscle/Cerebral Oxygenation
NCT07001176
Caffeine and Sport Climbing Performance
NCT07333443
Caffeine and Resistance Training in Older Adults
NCT06618261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caffeine supplementation
Acute caffeine supplementation
Caffeine
Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Placebo supplementation
Acute placebo supplementation
Placebo
Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caffeine
Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Placebo
Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Suffering from any chronic pathology or an injury in the month prior to the investigation
* Use of medicines or dietary supplements during the study.
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Rey Juan Carlos
OTHER
Universidad Miguel Hernandez de Elche
OTHER
University of Beira Interior
OTHER
Universidad Francisco de Vitoria
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alvaro L López Samanes, PhD
Role: PRINCIPAL_INVESTIGATOR
Universidad Francisco de Vitoria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidad Francisco de Vitoria
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lopez-Samanes A, Moreno-Perez V, Travassos B, Del Coso J. Effects of acute caffeine ingestion on futsal performance in sub-elite players. Eur J Nutr. 2021 Dec;60(8):4531-4540. doi: 10.1007/s00394-021-02617-w. Epub 2021 Jun 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Universidad Francisco Vitoria
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.